The expanding role of marine microbes in pharmaceutical development

Current Opinion in Biotechnology

Volumn 21, Issue 6, 2010, Pages 780-786

  Waters, Amanda L ^a   Hill, Russell T ^b   Place, Allen R ^b   Hamann, Mark T ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MARYLAND CENTER FOR ENVIRONMENTAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DRUG DESIGN; ENVIRONMENTAL CHANGE; FISH KILLS; HARMFUL ALGAL BLOOMS; MARINE MICROBE; MARINE NATURAL PRODUCTS; SERUM CHOLESTEROL;

ALGAE CONTROL; BACTERIA;

ENVIRONMENTAL IMPACT;

BRYOSTATIN; BRYOSTATIN 1; CHOLESTEROL; CYANOSAFRACIN B; CYTARABINE; DEHYDRODIDEMNIN B; ERIBULIN; HEMIASTERLIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRVALEC; ISOKAHALIDE; KARLOTOXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANZAMINE A; MARIZOMIB; NATURAL PRODUCT; OMEGA CONOTOXIN MVIIA; PLINABULIN; PM 00101; PM 00104; PSEUDOPTEROSIN DERIVATIVE; SALINISPORAMIDE DERIVATIVE; SOBLIDOTIN; TASODOTIN; TRABECTEDIN; UNCLASSIFIED DRUG; VIDARABINE; ZALYPSIS;

CELL DEATH; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CYTOTOXICITY TEST; DINOFLAGELLATE; DRUG APPROVAL; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HEART DISEASE; HUMAN; KARLODINIUM VENEFICUM; MARINE BACTERIUM; NEOPLASM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CHEMISTRY, PHARMACEUTICAL; DINOFLAGELLIDA; HARMFUL ALGAL BLOOM; MARINE BIOLOGY;

ALGAE; DINOPHYCEAE; KARLODINIUM;

EID: 78349305358     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2010.09.013     Document Type: Review

References (54)

1. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70:461-477.
2. Blunt J.W., Copp B.R., Hu W.-P., Munro M.H.G., Northcote P.T., Prinsep M.R. Marine natural products. Nat Prod Rep 2007, 24:31-86.
3. Mayer A.M., Glaser K.B., Cuevas C., Jacobs R.S., Kem W., Little R.D., McIntosh J.M., Newman D.J., Potts B.C., Shuster D.E. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 2010, 31:255-265.
4. Piel J. Metabolites from symbiotic bacteria. Nat Prod Rep 2009, 26:338-362.
5. Gulder T.A., Moore B.S. Chasing the treasures of the sea-bacterial marine natural products. Curr Opin Microbiol 2009, 12:252-260.
6. Schmidt E.W., Donia M.S. Life in cellulose houses: symbiotic bacterial biosynthesis of ascidian drugs and drug leads. Curr Opin Biotechnol 2010, this volume.
7. Trindade-Silva A.E., Lim-Fong G.E., Sharp K.H., Haygood M.G. Bryostatins: biological context and biotechnological prospects. Curr Opin Biotechnol 2010, this volume.
8. Kobayashi M., Natsume T., Tamaoki S., Watanabe J., Asano H., Mikami T., Miyasaka K., Miyazaki K., Gondo M., Sakakibara K., et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 1997, 88:316-327.
9. Ebbinghaus S., Rubin E., Hersh E., Cranmer L.D., Bonate P.L., Fram R.J., Jekunen A., Wietman S., Hammond L.A. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2005, 11:7807-7816.
10. Pettit G.R., Kamano Y., Fujii Y., Herald C.L., Inoue M., Brown P., Gust D., Kitahara K., Schmidt J.M., Doubek D.L., et al. Marine animal biosynthetic constituents for cancer chemotherapy. J Nat Prod 1981, 44:482-485.
11. Luesch H., Moore R.E., Paul V.J., Mooberry S.L., Corbett T.H. Isolation, of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 2001, 64:610-907.
12. Harrigan G.G., Yoshida W.Y., Moore R.E., Nagle D.G., Park P.U., Biggs J., Paul V.J., Mooberry S.L., Corbett T.H., Valeriote F.A. Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. J Nat Prod 1998, 61:1221-1225.
13. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003, 42:355-357.
14. Davidson S.K., Allen S.W., Lim G.E., Anderson C.M., Haygood M.G. Evidence for the biosynthesis of bryostatins by the bacterial symbiont " Candidatus Endobugula sertula" of the bryozoan Bugula neritina. Appl Environ Microbiol 2001, 67:4531-4537.
15. Yamazaki Y., Sumikura M., Hidaka K., Yasui H., Kiso Y., Yakushiji F., Hayashi Y. Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin. Bioorg Med Chem 2010, 18:3169-3174.
16. Fenical WDM, Jensen PR, Cheng XC: Halimide, a cytotoxic marine natural product, and derivatives thereof. US 6069146 A. Publ. 5/30/2000.
17. Kanoh K., Kohno S., Katada J., Hayashi Y., Muramatsu M., Uno I. Antitumor activity of phenylahistin in vitro and in vivo. Biosci Biotechnol Biochem 1999, 63:1130-1133.
18. Cuevas C., Francesch A. Development of Yondelis (trabectedin, ET-743): a semisynthetic process solves the supply problem. Nat Prod Rep 2009, 26:322-337.
19. Ocio E.M., Maiso P., Chen X., Garayoa M., Alvarez-Fernandez S., San-Segundo L., Vilanova D., Lopez-Corral L., Montero J.C., Hernandez-Iglesias T., et al. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2009, 113:3781-3791.
20. Mikami Y., Takahashi K., Yazawa K., Arai T., Namikoshi M., Iwasaki S., Okuda S. Biosynthetic studies on saframycin A, a quinone antitumor antibiotic produced by Streptomyces lavendulae. J Biol Chem 1985, 260:344-348.
21. Cuevas C., Perez M., Martin M.J., Chicharro J.L., Fernandez-Rivas C., Flores M., Francesch A., Gallego P., Zarzuelo M., de la Calle F., et al. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett 2000, 2:2545-2548.
22. Newman S. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs 2007, 8:1057-1066.
23. Demydchuk Y., Sun Y., Hong H., Staunton J., Spencer J.B., Leadlay P.F. Analysis of the tetronomycin gene cluster: insights into the biosynthesis of a polyether tetronate antibiotic. Chembiochem 2008, 9:1136-1145.
24. Harvey B.M., Mironenko T., Sun Y., Hong H., Deng Z., Leadlay P.F., Weissman K.J., Haydock S.F. Insights into polyether biosynthesis from analysis of the nigericin biosynthetic gene cluster in Streptomyces sp. DSM4137. Chem Biol 2007, 14:703-714.
25. Hoshi M., Endo T. Microbial and chemical conversion of antibiotic K41. II. Preparation of K41-DA1-DA2 and -DA3 deamicetosyl derivatives of antibiotic K41. J Antibiot (Tokyo) 2000, 53:1154-1157.
26. Beer L.L., Moore B.S. Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinispora tropica. Org Lett 2007, 9:845-848.
27. Sudek S., Lopanik N.B., Waggoner L.E., Hildebrand M., Anderson C., Liu H., Patel A., Sherman D.H., Haygood M.G. Identification of the putative bryostatin polyketide synthase gene cluster from " Candidatus Endobugula sertula" , the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J Nat Prod 2007, 70:67-74.
28. Hill RT, Hamann MT, Enticknap J, Rao KV, Fuierer M: Kahalalide-Producing Bacteria. WO 2005/042720 A3. Publ. 5/12/2005.
29. Hamann M.T. The manzamines as an example of the unique structural classes available for the discovery and optimization of infectious disease controls based on marine natural products. Curr Pharm Des 2007, 13:653-660.
30. Rao K.V., Donia M.S., Peng J., Garcia-Palomero E., Alonso D., Martinez A., Medina M., Franzblau S.G., Tekwani B.L., Khan S.I., et al. Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod 2006, 69:1034-1040.
31. Peng J., Kudrimoti S., Prasanna S., Odde S., Doerksen R.J., Pennaka H.K., Choo Y., Rao K.V., Tekwani B.L., Madgula V., et al. Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J Med Chem 2010, 53:61-76.
32. Hill RT, Hamann MT, Peraud O, Kasanah N: Manzamine Producing Actinomycetes. WO 2004/013297A3. Publ. 2/12/2004.
33. Baldwin J.E.W.R. Biosyntheis of manzamines. Tetrahedron Lett 1992, 33:2059-2062.
34. Adolf J.E., Bachvaroff T.R., Place A.R. Environmental modulation of karlotoxin levels in strains of the cosmopolitan dinoflagellate, Karlodinium veneficum (Dinophyceae). J Phycol 2009, 45:176-192.
35. Wang D. Neurotoxins from marine dinoflagellates: a brief review. Mar Drugs 2008, 6:349-371.
36. Peng J., Hill R., Place A., Anklin C., Hamann M.T. Marine microbes: the critical role they play in sustainable production of starting materials for the synthesis of drug leads and the structure for the elusive Pfiesteria-associated fish killing toxin using 13C enrichment and dual cryoprobe NMR studies. Abstracts of Papers, 233rd ACS National Meeting 2007.
37. Bachvaroff T.R., Adolf J.E., Squier A.H., Harvey H.R., Place A.R. Characterization and quantification of karlotoxins by liquid chromatography-mass spectrometry. Harmful Algae 2008, 7:473-484.
38. Place AR, Deeds JR: Dinoflagellate Karlotoxins, Methods of Isolation and Uses Thereof. WO 2004/100659 A2. Publ. 11/25/2004.
39. Peng J., Place A.R., Yoshida W., Clemens A., Hamann M.T. Structure and absolute configuration of karlotoxin-2, an ichthyotoxin from the marine dinoflagellate Karlodinium veneficum. J Am Chem Soc 2010, 132:3277-3279.
40. Van Wagoner R.M., Deeds J.R., Satake M., Ribeiro A.A., Place A.R., Wright J.L.C. Isolation and characterization of karlotoxin 1, a new amphipathic toxin from Karlodimiun veneficum. Tetrahedron Lett 2008, 49:6457-6461.
41. Sheng J., Malkiel E., Katz J., Adolf J.E., Place A.R. A dinoflagellate exploits toxins to immobilize prey prior to ingestion. Proc Natl Acad Sci 2010, 107:2082-2087.
42. Place A.R., Bai X., Kim S., Sengco M.R., Coats D.W. Dinoflagellate host-parasite sterol profiles dictate karlotoxin sensitivity. J Phycol 2009, 45:375-385.
43. Berg J., Tymoczko J., Stryer L. The Biosynthesis of Membrane Lipids and Steroids. Biochemistry 2002, W.H. Freeman and Company, chapter 26.
44. American Heart Association: Cholesterol. [cited 2010; available from ]. http://www.americanheart.org/presenter.jhtml?identifier=4488.
45. Ablan S., Rawat1 S., Viard M., Wang J., Puri A., Blumenthal R. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. Virol J 2006, 3:104.
46. Luo C., Wang K., Liu D., Li Y., Zhao O. The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention. Cell Mol Immunol 2008, 5:1-7.
47. Fantini J., Garmy N., Mahfoud R., Yahi N. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Expert Rev Mol Med 2002, 20. 10.1017/S1462399402005392.
48. Fantini F., Barrantes F. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta 2009, 1788:2345-2361.
49. Agargun M., Dulger H., Inci R., Kara H., Ozer O., Sekeroglu M., Besiroglu L. Serum lipid concentrations in obsessive-compulsive disorder patients with and without panic attacks. Can J Psychiatry 2004, 49:776-778.
50. Pandey A., Sassetti C. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci 2008, 105:4376-4380.
51. Alchorn A: Lipid rafts observed in cell membranes. Sci Tech Rev 2007, 9 [cited 2010; available from ]. https://www.llnl.gov/str/May07/Ratto.html.
52. Simons K., Ehehalt R. Cholesterol, lipid rafts and disease. J Clin Invest 2002, 110:597-603.
53. Li Y., Park M., Ye S., Kim C., Kim Y. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006, 168:1107-1118.
54. Solomon K., Pelton K., Boucher K., Joo J., Tully C., Zurakowski D., Schaffner C., Kim J., Freeman M. Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 2009, 174:1017-1026.